
David J. Parsley
Examiner (ID: 8737, Phone: (571)272-6890 , Office: P/3643 )
| Most Active Art Unit | 3643 |
| Art Unit(s) | 3643 |
| Total Applications | 2056 |
| Issued Applications | 931 |
| Pending Applications | 179 |
| Abandoned Applications | 973 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17212973
[patent_doc_number] => 20210346309
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => UNIMOLECULAR NANOPARTICLES FOR EFFICIENT DELIVERY OF THERAPEUTIC RNA
[patent_app_type] => utility
[patent_app_number] => 17/331012
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10370
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17331012
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/331012 | UNIMOLECULAR NANOPARTICLES FOR EFFICIENT DELIVERY OF THERAPEUTIC RNA | May 25, 2021 | Abandoned |
Array
(
[id] => 18436413
[patent_doc_number] => 20230183707
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING MARC1 GENE EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/999320
[patent_app_country] => US
[patent_app_date] => 2021-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72125
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999320
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999320 | COMPOSITIONS AND METHODS FOR INHIBITING MARC1 GENE EXPRESSION | May 20, 2021 | Pending |
Array
(
[id] => 18449595
[patent_doc_number] => 20230190871
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/926564
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 86761
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926564
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926564 | METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS | May 18, 2021 | Abandoned |
Array
(
[id] => 18673160
[patent_doc_number] => 20230310652
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => VLP FOR THE TREATMENT OF LEUKODYSTROPHIES
[patent_app_type] => utility
[patent_app_number] => 17/926678
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17912
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926678
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926678 | VLP FOR THE TREATMENT OF LEUKODYSTROPHIES | May 18, 2021 | Abandoned |
Array
(
[id] => 18418650
[patent_doc_number] => 20230173108
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => COMPOSITIONS USEFUL FOR TREATMENT OF POMPE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/998371
[patent_app_country] => US
[patent_app_date] => 2021-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998371
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998371 | COMPOSITIONS USEFUL FOR TREATMENT OF POMPE DISEASE | May 13, 2021 | Abandoned |
Array
(
[id] => 18565766
[patent_doc_number] => 20230256093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => METHOD
[patent_app_type] => utility
[patent_app_number] => 17/924345
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19702
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924345
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/924345 | METHOD | May 11, 2021 | Pending |
Array
(
[id] => 17336393
[patent_doc_number] => 20220002724
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/314909
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 99870
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314909
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/314909 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | May 6, 2021 | Pending |
Array
(
[id] => 18449678
[patent_doc_number] => 20230190954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA
[patent_app_type] => utility
[patent_app_number] => 17/923839
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36497
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923839
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923839 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | May 6, 2021 | Pending |
Array
(
[id] => 17385963
[patent_doc_number] => 20220033815
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 17/307350
[patent_app_country] => US
[patent_app_date] => 2021-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49637
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307350
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/307350 | SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES | May 3, 2021 | Abandoned |
Array
(
[id] => 17035080
[patent_doc_number] => 20210252038
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => COMBINATION THERAPIES FOR INNER EAR SENSORY HAIR CELL REGENERATION/REPLACEMENT
[patent_app_type] => utility
[patent_app_number] => 17/241001
[patent_app_country] => US
[patent_app_date] => 2021-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15070
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241001
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/241001 | COMBINATION THERAPIES FOR INNER EAR SENSORY HAIR CELL REGENERATION/REPLACEMENT | Apr 25, 2021 | Pending |
Array
(
[id] => 18376284
[patent_doc_number] => 20230151367
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS
[patent_app_type] => utility
[patent_app_number] => 17/920682
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24837
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920682
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/920682 | THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS | Apr 22, 2021 | Pending |
Array
(
[id] => 17428734
[patent_doc_number] => 20220056442
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 17/234541
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26077
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17234541
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/234541 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | Apr 18, 2021 | Abandoned |
Array
(
[id] => 17444144
[patent_doc_number] => 20220064649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => SPHERICAL NUCLEIC ACID TLR9 AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/231896
[patent_app_country] => US
[patent_app_date] => 2021-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17231896
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/231896 | SPHERICAL NUCLEIC ACID TLR9 AGONISTS | Apr 14, 2021 | Abandoned |
Array
(
[id] => 17007441
[patent_doc_number] => 20210238602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use
[patent_app_type] => utility
[patent_app_number] => 17/231479
[patent_app_country] => US
[patent_app_date] => 2021-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47234
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -53
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17231479
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/231479 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | Apr 14, 2021 | Pending |
Array
(
[id] => 19969849
[patent_doc_number] => 12338442
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-24
[patent_title] => Aptamers against clostridium difficile
[patent_app_type] => utility
[patent_app_number] => 17/228994
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 72
[patent_no_of_words] => 17106
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228994
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/228994 | Aptamers against clostridium difficile | Apr 12, 2021 | Issued |
Array
(
[id] => 19855736
[patent_doc_number] => 12258560
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-25
[patent_title] => Compositions and methods for transient gene therapy with enhanced stability
[patent_app_type] => utility
[patent_app_number] => 17/225823
[patent_app_country] => US
[patent_app_date] => 2021-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 48
[patent_no_of_words] => 15457
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17225823
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/225823 | Compositions and methods for transient gene therapy with enhanced stability | Apr 7, 2021 | Issued |
Array
(
[id] => 17461620
[patent_doc_number] => 20220074925
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/221457
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22280
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/221457 | SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS | Apr 1, 2021 | Abandoned |
Array
(
[id] => 18345078
[patent_doc_number] => 20230133188
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => MODIFIED MRNAS FOR VACCINE DEVELOPMENT
[patent_app_type] => utility
[patent_app_number] => 17/912402
[patent_app_country] => US
[patent_app_date] => 2021-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12808
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17912402
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/912402 | MODIFIED MRNAS FOR VACCINE DEVELOPMENT | Mar 18, 2021 | Pending |
Array
(
[id] => 18321571
[patent_doc_number] => 20230119699
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => DIAGNOSTIC METHODS USING SIRT1 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/906175
[patent_app_country] => US
[patent_app_date] => 2021-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36406
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -73
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906175
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/906175 | DIAGNOSTIC METHODS USING SIRT1 EXPRESSION | Mar 11, 2021 | Pending |
Array
(
[id] => 19250180
[patent_doc_number] => 20240201168
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => COMPOSITION FOR DIAGNOSIS OR TREATMENT OF ANTICANCER DRUG RESISTANCE
[patent_app_type] => utility
[patent_app_number] => 17/905491
[patent_app_country] => US
[patent_app_date] => 2021-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20186
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905491
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/905491 | COMPOSITION FOR DIAGNOSIS OR TREATMENT OF ANTICANCER DRUG RESISTANCE | Mar 1, 2021 | Pending |